Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · June 27, 2013

Significant Survival Benefit Conferred With Doublet Chemotherapy in Advanced NSCLC and ECOG PS 2

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non-Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
J. Clin. Oncol 2013 Jun 17;[EPub Ahead of Print], M Zukin, CH Barrios, J Rodrigues Pereira, R De Albuquerque Ribeiro, CA de Mendonça Beato, YN do Nascimento, A Murad, FA Franke, M Precivale, LH de Lima Araujo, CS Da Rocha Baldotto, FM Vieira, IA Small, CG Ferreira, RC Lilenbaum

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading